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Abstract
Background: A drug resistance survey is an essential public health management tool for evaluating
and improving the performance of National Tuberculosis control programmes. The current
manuscript describes the implementation of the first national drug resistance survey in Tanzania.
Methods:  Description of the implementation process of a national anti-tuberculosis drug
resistance survey in Tanzania, in relation to the study protocol and Standard Operating Procedures.
Results: Factors contributing positively to the implementation of the survey were a continuous
commitment of the key stakeholders, the existence of a well organized National Tuberculosis
Programme, and a detailed design of cluster-specific arrangements for rapid sputum transportation.
Factors contributing negatively to the implementation were a long delay between training and
actual survey activities, limited monitoring of activities, and an unclear design of the data capture
forms leading to difficulties in form-filling.
Conclusion: Careful preparation of the survey, timing of planned activities, a strong emphasis on
data capture tools and data management, and timely supervision are essential for a proper
implementation of a national drug resistance survey.
Background
Drug resistance can occur due to inadequate management
of treatment or transmission of drug resistant strains.
Multi-drug resistant tuberculosis (MDR-TB) is defined as
tuberculosis (TB) resistant to isoniazid and rifampicin,
the two main first-line drugs in the treatment of TB. In
2006, nearly 500,000 new MDR-TB patients were identi-
fied worldwide[1]. Treatment of these patients is feasible
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but is substantially more costly than treating patients with
fully susceptible Mycobacterium Tuberculosis strains[2].
The growing prevalence of MDR and the emerging threat
of XDR-TB (MDR-TB with additional resistance to at least
any of the fluroquinolones and one of the three injectable
second-line TB drugs) urged the World Health Organiza-
tion (WHO) to form a global task force on MDR/XDR-TB
[3], which charged the Working Group on MDR-TB of the
STOP TB Partnership to develop a response plan to
address this emergence[4]. In this, countries are advised to
perform drug resistance surveys to be able to provide
insight in the magnitude of the resistance problem. Given
the underlying causes of drug resistance, information on
TB drug resistance levels is an essential public health man-
agement tool for evaluating and improving the perform-
ance of the National TB control Programmes (NTPs), and
indicates the difficulties which NTPs will encounter when
administering chemotherapy[1,3,4].
For the United Republic of Tanzania, information on TB-
drug resistance is available from studies covering specific
districts or diagnostic facilities[5], in the context of TB-
HIV studies[6,7], and from baseline information of
patients enrolling in a randomised clinical trial[8]. All of
these studies showed low levels of drug resistance and
MDR. The routine data analysed from the Central Tuber-
culosis Reference Laboratory (CTRL) also showed low lev-
els of drug resistance of Mycobacterium tuberculosis strains
tested from 1991 to 1999. Rates were 10% to any drug,
5.6% to isoniazid, 0.5% to rifampicin, 0.6% to ethambu-
tol, 1.4% to streptomycin and around 1% to isoniazid and
rifampicin (MDR-TB).
The data of these studies and of the routinely collected
specimens are not adequately informative on the preva-
lence of drug resistance on a national level, because spec-
imens were not collected from a representative sample of
TB patients throughout the country, and the surveys were
not in accordance with current internationally recom-
mended methodology[9]. The only national surveys on
drug resistance were carried out before or just after the
introduction of current TB-control strategies [10-12]. For
this reason, the National Tuberculosis and Leprosy Pro-
gramme (NTLP) of Tanzania has implemented for the first
time a drug resistance survey (DRS) on a national repre-
sentative sample of TB patients identified in the country.
The current manuscript describes the methodology used,
the logistics involved, and the factors contributing to its
implementation. The positive and negative lessons
learned from the implementation of the survey can be
used by other countries that are embarking on a similar
survey.
Methods
Study population and sample size
The DRS is implemented in 40 diagnostic centres
(denoted as clusters) which were sampled proportional to
patient load (new smear-positive cases) from all diagnos-
tic centres notifying TB cases to the NTLP. Each cluster
enrolled 30 consecutive new smear-positive TB cases,
arriving at a self-weighting study sample. During the
enrolment time, the clusters were required to enrol con-
secutively all re-treatment cases diagnosed. Inclusion
closed after 12 months even if enrolment of required cases
was not complete.
Inclusion criteria
All sputum-positive patients diagnosed during the inclu-
sion period were eligible to be enrolled in the study.
Smear-positivity was diagnosed according to the national
guidelines requiring at least two out of three sputum sam-
ples showing acid-fast bacilli by Ziehl Neelsen (ZN)
microscopy. A re-treatment case was defined as a patient
with smear-positive TB who received treatment for TB for
more than one month. All other patients were classified as
new.
Sample collection and processing
All diagnosed patients provided a new morning sputum
specimen the next day. This specimen was sent to CTRL
without interfering with. If the expected transit time
between cluster and CTRL was assessed to take longer than
4 days, two morning specimens were collected; one with
Cetyl-Pyridinium-Chloride (CPC) and one without CPC
added for preservation purposes[13,14]. All specimens
were examined by ZN microscopy and culture. Culture
was performed on solid Loewenstein Jensen medium after
decontamination by modified Petroff's method. The
results of the sensitivity tests were interpreted with the
proportion method[15].
The study was approved by the National Ethical Commit-
tee which has its secretariat at National Institute for Med-
ical Research.
Results
Initiation of the study
The initial discussions of implementing the DRS started as
early as 2002 amongst the major stakeholders including
NTLP, WHO, Institute of Tropical Medicine in Antwerp,
KNCV Tuberculosis Foundation in The Netherlands, and
the National Institute for Medical Research, Muhimbily
Centre in Tanzania. Figure 1 shows the timeline of the
DRS in Tanzania. It can be seen that factors related to
infrastructure, personnel, finance, and time all played a
crucial role in the long duration of the DRS from initia-
tion to analysis.BMC Public Health 2008, 8:427 http://www.biomedcentral.com/1471-2458/8/427
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From an initial budget of 20,000 USD, the study costs
increased up to 100,000 USD at the actual start of the
study due to increased costs of personnel, transport
arrangements for specimens, and supplies. The continu-
ous commitment of the stakeholders towards the study
and the willingness to meet the rising financial demands
proved to be instrumental in the final implementation of
the study 4 years later.
Preparation of the study
An essential step in the successful implementation was the
pre-survey visit to each selected cluster by a laboratory-
experienced member of the study team. The cluster was
assessed using a pre-defined checklist for personnel,
equipment, and infrastructure. The biggest gain of these
visits was that a detailed and novel cluster-specific plan for
transporting the samples to CTRL was made.
Special contracts with bus companies were negotiated that
agreed on delivery of the samples and the costs involved.
Because bus companies were paid upfront, there was no
need to negotiate charges when the samples were sent.
Staff of the clusters was given mobile phone top-up cards
to be able to call CTRL to inform that samples were put on
the bus. CTRL staff then went to the delivery point for
pick-up. For clusters close to CTRL, 'specimen boys' were
hired who's sole task was to collect samples at the clusters
and bring them to CTRL in person. These individuals were
paid per quarter assuring their continuous commitment
to the job. Transport containers and CPC were provided
for by the programme and distributed prior to the study.
The organization of the travel arrangements took several
months to complete, but paid off. In routine settings, the
specimens from the remote areas would have been sent by
mail and take up to several weeks to arrive at CTRL. Dur-
ing the DRS, the median transport time of all samples was
reduced to only 5 days and stayed this low during the
entire survey. This includes specimens from remote areas.
Consequently, the yield of the culture was above 90%.
This could not have been achieved without paying much
detail to the logistic involved in sample transportation.
Training of study personnel
The training of all the study personnel took place at six
different places and was organised by the staff from CTRL.
In the two-day event, the participants were informed on
the rationale for the study, the protocol, and the data cap-
ture forms. The participants engaged in a practical exercise
on interview-taking and form-filling.
An important factor negatively influencing the implemen-
tation of the DRS was the long time between the training
and the actual start of the survey. For some clusters, this
delay ran up to 9 months. In that time, especially admin-
istrative issues related to the form-filling were often for-
gotten. In all clusters, at least one, but sometimes all,
trained staff member was replaced between training and
start of survey activities in the cluster. The budget did not
foresee training of the replacement staff. Instead, new staff
was trained on-the-spot by laboratory personnel who had
received the initial training. This situation resulted in reg-
ularly observed incomplete data capture forms with inter-
nally inconsistent data. This complicated data
management and data validation procedures, which
increased the workload of CTRL staff.
Implementation of the study
All clusters performed a pilot study in four TB-suspects to
assess the study procedures and the transport of speci-
mens. No major issues came to light during the pilot
study, although the actual processing of the specimens
and the data recording were not part of the test. This
shows that results from pilot studies are only useful if no
major changes in the study activities occur. The change in
research staff during the survey made it impossible to
meet this prerequisite.
The factor that had the largest influence on the implemen-
tation of the study was the design of the data capture
forms, which were not formally pre-tested. This resulted
in frequently observed incomplete data capture forms,
especially regarding study number and type of patient
(new or retreatment). To be able to monitor the inclusion
in the study, all forms were recoded manually from the
Time line and constraints drug resistance survey Tanzania Figure 1
Time line and constraints drug resistance survey Tanzania.
First patient in
2002
* Introduce new DST method in CTRL
* Ongoing proficiency testing
* Concurrent other studies
June 2003 July 2006 November 2005 August 2005 July  2005
Identified need Final protocol Initial protocol SOP developed
February 2008
Training
August 2007
Last patient out Data complete
* Relocation CTRL
* Delay lab equipment
* Delay in access to funds
* Delay in procurement
* Delay in access to funds
* Incomplete pilot
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midpoint of the survey onwards. This identified 13 (32%)
clusters that had stopped submitting samples before
reaching the target enrolment. Thirty-five (3%) extra sam-
ples were received afterwards from these clusters.
The final classification on the type of patient was absent
for 292 (19.2%) of the 1520 data capture forms. Of these,
85 had no interview data recorded at all. The status of
these patient was derived by contacting the cluster. All
remaining forms with incomplete interview data (n =
207) were assessed manually at the end of the study to
classify the type of patient.
Apart from these two critical variables, age was not
recorded on 42 (3%) forms, sex not on 5 (0.3%), and date
of specimen not on 54 (3.6%).
The problems with the form-filling could not be solved
during the survey because the largest clusters recruited
their patients in a very short time frame. This made mon-
itoring visits being too late. Monitoring visits that were
planned for the other clusters were not implemented fully
due to lack of personnel and difficulties in access to funds.
As an alternative, a statistical syntax was written that could
identify missing data and internal inconsistencies. This
syntax was run on updates from the database at regular
intervals. The identified database records with errors were
manually checked against the data capture forms and cor-
rected where needed. Issues that could not be solved by
this procedure were corrected during routine supervision
visits to the clusters by the NTLP.
These negative influences need to be anticipated by coun-
tries that are embarking on a similar survey. There can be
not enough emphasis on pre-testing of data capture forms
and frequent monitoring of data collection. Post-hoc cor-
rections of errors and inconsistencies will delay the report-
ing of the results and the use of the results by the NTLP for
planning purposes.
The processing of the specimens during the study was
without major technical problems. The progress was,
however, hampered by the unexpected lack of equipment,
leading to a constant backlog in sensitivity testing on
already performed cultures. The ability to carry out fre-
quent sub-culturing assured that no samples were lost for
the survey, but added to the workload of the laboratory
personnel. The delay in sensitivity testing caused that
patients and their treatment providers were not informed
on the presence of drug resistance, what can be seen as
missed opportunity to contribute to individual patient
care. Also, the delay in sensitivity testing precluded early
guidance from the supranational reference laboratory
(SNRL) in Antwerp on the DST technique. Despite this,
the ongoing proficiency testing by the SNRL showed a
high level of accuracy of the susceptibility testing of the
samples from routine surveillance. In the latest round of
testing, the efficiency (ratio between correct results and
total results) of CTRL was 100% for isoniazid, 97% for
rifampicin, 93% for streptomycin, and 100% for etham-
butol. Since this technique is exactly the same as the tech-
nique used in the survey, the quality of the DST results in
the survey is assured.
Data management
All information needed for the study was documented in
study-specific registers at CTRL. The main challenge was to
transfer the information from the registers to the data cap-
ture forms and making them available for data entry. The
data manager of the NTLP was not involved in the study
due to other activities. No replacement was employed.
Therefore, monitoring of data management was only per-
formed during visits of a technical advisor from abroad.
This is an undesirable situation because it delays assess-
ment of the data, precludes adjusting data entry errors,
and lacks capacity building activities within the NTLP.
Countries that will embark on a DRS should invest in
proper data entry and data management personnel that
can perform the activities in real-time.
Discussion
The initiation, preparation and implementation of the
DRS turned out to be challenging. The whole process
revealed some valuable lessons to be learned that are sum-
marized in Table 1.
Ensuring the ongoing commitment for the study from key
stakeholders proofed to be vital. Without this commit-
ment there would have been no drive to address the prob-
lems identified before and during implementation. It
assures that the final data will be used for planning pur-
poses of the NTLP.
The issues that influenced the conduct of the survey nega-
tively are well known in the field of project management.
It remains surprising to see how large the impact of these
issues is on the efficient implementation of a study. Most
national tuberculosis programmes do not have the luxury
of being able to free personnel solely for research pur-
poses, making it difficult to perform efficient research.
However, engaging research scientists from research insti-
tutions that are able to give 100% person time for the
project could be an alternative solution and backup to the
program. This can work very well provided upfront agree-
ment and commitment in collaboration is secured.
The DRS in Tanzania showed that detailed design of data
capture tools, investment in data entry personnel, data
management personnel, and frequent monitoring visits
can avoid many of the problems encountered in theBMC Public Health 2008, 8:427 http://www.biomedcentral.com/1471-2458/8/427
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present survey. In any DRS where sampling is performed
proportional to patient load, there will be clusters that fin-
ish quickly with enrolment. These clusters should be the
primary focus of the initial monitoring. Not only will this
ensure valid data from these clusters, it will also guide the
monitoring in other clusters on issues that only arise in a
real-life situation rather than in a pilot study.
Conclusion
The design and implementation of the drug resistance sur-
vey in Tanzania was a large undertaking which needed
continuous commitment, adequate funding, enough per-
sonnel and equipment. Although well known project
management issues were addressed in the design phase of
the study, these still influenced the actual implementation
at each stage of the project. Only with additional data val-
idation measures was it possible to arrive at a valid data
base that can be used for answering the research ques-
tions. Although NTP managers who are embarking on
such a survey will have country-specific issues to solve, the
lessons learned during the survey in Tanzania could pro-
vide precious guidance and facilitate the smooth imple-
mentation of such an important activity.
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